Biohaven Pharmaceutical Holding Co Ltd (BHVN) Director Sells $1,435,500.00 in Stock

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Gregory Bailey sold 50,000 shares of the company’s stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $28.71, for a total transaction of $1,435,500.00. Following the completion of the transaction, the director now directly owns 1,187,275 shares in the company, valued at $34,086,665.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Gregory Bailey also recently made the following trade(s):

  • On Wednesday, December 20th, Gregory Bailey sold 39,430 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $26.31, for a total transaction of $1,037,403.30.
  • On Thursday, November 30th, Gregory Bailey sold 9,970 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $25.48, for a total transaction of $254,035.60.
  • On Friday, November 24th, Gregory Bailey sold 600 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $26.02, for a total transaction of $15,612.00.
  • On Monday, November 27th, Gregory Bailey sold 20,600 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $25.92, for a total transaction of $533,952.00.

Biohaven Pharmaceutical Holding Co Ltd (NYSE BHVN) opened at $29.96 on Monday. The company has a market cap of $1,080.00 and a price-to-earnings ratio of -5.74. Biohaven Pharmaceutical Holding Co Ltd has a 1 year low of $17.00 and a 1 year high of $39.51.

Several research firms have commented on BHVN. Zacks Investment Research downgraded shares of Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Tuesday, December 19th. BidaskClub downgraded shares of Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Thursday, October 5th. Piper Jaffray Companies reissued a “buy” rating and set a $54.00 target price on shares of Biohaven Pharmaceutical in a research report on Tuesday, September 12th. Canaccord Genuity began coverage on shares of Biohaven Pharmaceutical in a research report on Friday, December 15th. They set a “buy” rating and a $30.00 target price on the stock. Finally, William Blair reissued an “outperform” rating on shares of Biohaven Pharmaceutical in a research report on Tuesday, October 3rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $36.14.

Large investors have recently modified their holdings of the company. Deschutes Portfolio Strategy LLC acquired a new stake in shares of Biohaven Pharmaceutical in the third quarter valued at about $374,000. Artal Group S.A. acquired a new stake in shares of Biohaven Pharmaceutical in the third quarter valued at about $1,869,000. Strs Ohio acquired a new stake in shares of Biohaven Pharmaceutical in the third quarter valued at about $680,000. Susquehanna International Group LLP acquired a new stake in shares of Biohaven Pharmaceutical in the third quarter valued at about $302,000. Finally, Eagle Asset Management Inc. acquired a new stake in shares of Biohaven Pharmaceutical in the third quarter valued at about $32,635,000. 47.76% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally reported by Equities Focus and is the sole property of of Equities Focus. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.equitiesfocus.com/2018/01/08/biohaven-pharmaceutical-holding-co-ltd-bhvn-director-sells-1435500-00-in-stock.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply